Company Profile of Changchun BCHT Biotechnology Co.

Changchun BCHT Biotechnology Co was established in March 2004 by the investment of Changchun High-technology Industry Development Property (Group)(Stock code: 000661.SZ). BCHT is a listed and high-tech enterprise engaged in R&D, production and marketing of biologics and drugs. In 2008, BCHT successfully launched its product Varicella Vaccine, Live in China. In the following years, BCHT continuously committed to improving the product and led in 2010 removal of gelatin from adjuvant and extension of the vaccine shelf-life up to 36 months which is the longest one in the world.

BCHT now covers 235,000 square meters for manufacturing sites and owns two R&D centers for vaccine and drug with the most equipped laboratories and pilot plants in the areas over 5000 square meters. For the last few years, the company’s R&D investment exceeds over 400 million RMB.

BCHT has been awarded as High-tech Enterprise, AAA Credit Enterprise, Quality Creditable Enterprise and assigned as Engineering Research Center for Modern Vaccines, Innovative Center for Science and Technology of Vaccine, Engineering Research Center for Vaccines at Changchun State Bio-Industry Base by Jilin province. BCHT has co-established National Engineering Laboratory for AIDS Vaccine with Jilin University.